Overview
Availability
- Dr Yaowu He is:
- Available for supervision
Works
Search Professor Yaowu He’s works on UQ eSpace
2025
Journal Article
Receptor CDCP1 is a potential target for personalized imaging and treatment of poor outcome HER2+, triple negative and metastatic ER+/HER2- breast cancers
Gough, Madeline, Kwah, Kayden KX., Khan, Tashbib, Ghosh, Saikat, Sun, Biao, Lee, Catherine YJ., Sokolowski, Kamil A., Tse, Brian WC., Wickramasuriya, Lashith, Ferguson, Kaltin, Rogers, Rebecca, Goh, Justin B., Fletcher, Nicholas L., Houston, Zachary H., Thurecht, Kristofer J., Bray, Laura J., Liu, Cheng, Pyke, Christopher, Lim, Elgene, Snell, Cameron E., He, Yaowu, Hooper, John D. and Kryza, Thomas (2025). Receptor CDCP1 is a potential target for personalized imaging and treatment of poor outcome HER2+, triple negative and metastatic ER+/HER2- breast cancers. Clinical Cancer Research, 31 (8), OF1-OF16. doi: 10.1158/1078-0432.ccr-24-2865
2024
Journal Article
Aurora B inhibitors promote RB hypophosphorylation and senescence independent of p53-dependent CDK2/4 inhibition
Vora, Shivam, Andrew, Ariel, Kumar, Ramyashree Prasanna, Nazareth, Deborah, Bonfim-Melo, Alexis, Lim, Yoon, Ong, Xin Yee, Fernando, Madushan, He, Yaowu, Hooper, John D., McMillan, Nigel A. J., Urosevic, Jelena, Travers, Jon, Saeh, Jamal, Kumar, Sharad, Jones, Mathew J. K. and Gabrielli, Brian (2024). Aurora B inhibitors promote RB hypophosphorylation and senescence independent of p53-dependent CDK2/4 inhibition. Cell Death & Disease, 15 (11) 810, 810. doi: 10.1038/s41419-024-07204-5
2024
Journal Article
Identification and characterization of TM4SF1+ tumor self-seeded cells
Yang, Haotian, Wang, Haolu, He, Yaowu, Yang, Yang, Thompson, Erik W., Xia, Di, Burke, Leslie J., Cao, Lu, Hooper, John D., Roberts, Michael S., Crawford, Darrell H.G. and Liang, Xiaowen (2024). Identification and characterization of TM4SF1+ tumor self-seeded cells. Cell Reports, 43 (7) 114512, 1-24. doi: 10.1016/j.celrep.2024.114512
2024
Journal Article
Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells
Shah, Esha T., Molloy, Christopher, Gough, Madeline, Kryza, Thomas, Samuel, Selwin G., Tucker, Amos, Bhatia, Maneet, Ferguson, Genevieve, Heyman, Rebecca, Vora, Shivam, Monkman, James, Bolderson, Emma, Kulasinghe, Arutha, He, Yaowu, Gabrielli, Brian, Hooper, John D., Richard, Derek J., O’Byrne, Kenneth J. and Adams, Mark N. (2024). Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells. British Journal of Cancer, 130 (7), 1196-1205. doi: 10.1038/s41416-024-02584-z
2023
Journal Article
MUC13 cell surface mucin limits Salmonella Typhimurium infection by protecting the mucosal epithelial barrier
McGuckin, Michael A., Davies, Julie M., Felgner, Pascal, Wong, Kuan Yau, Giri, Rabina, He, Yaowu, Moniruzzaman, Md., Kryza, Thomas, Sajiir, Haressh, Hooper, John D., Florin, Timothy H., Begun, Jakob, Oussalah, Abderrahim, Hasnain, Sumaira Z., Hensel, Michael and Sheng, Yong H. (2023). MUC13 cell surface mucin limits Salmonella Typhimurium infection by protecting the mucosal epithelial barrier. Cellular and Molecular Gastroenterology and Hepatology, 16 (6), 985-1009. doi: 10.1016/j.jcmgh.2023.08.011
2023
Conference Publication
Structural basis of an anti-cancer biological warhead bound to its target CDCP1 for the diagnosis and treatment of epithelial cancers
Kwah, Kayden, Gu, Weixi, Arachchige, Kasun S. A., He, Yaowu, Landsberg, Michael, Kobe, Bostjan and Hooper, John (2023). Structural basis of an anti-cancer biological warhead bound to its target CDCP1 for the diagnosis and treatment of epithelial cancers. XXVI IUCr Congress, Melbourne, VIC Australia, 22-29 August 2023. Hoboken, NJ United States: Wiley-Blackwell. doi: 10.1107/s2053273323084449
2023
Conference Publication
Development of a CUB domain-containing protein 1 (CDCP1)-targeting antibody-drug conjugate for triple-negative and metastatic breast cancer
Gough, Madeline, Kwah, Kayden, He, Yaowu, Snell, Cameron Edward, Hooper, John D. and Kryza, Thomas (2023). Development of a CUB domain-containing protein 1 (CDCP1)-targeting antibody-drug conjugate for triple-negative and metastatic breast cancer. 2023 ASCO Annual Meeting, Chicago, IL United States, 2-6 June 2023. Alexandria, VA United States: American Society of Clinical Oncology (ASCO). doi: 10.1200/jco.2023.41.16_suppl.e15012
2023
Journal Article
Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma
Raninga, Prahlad V., He, Yaowu, Datta, Keshava K., Lu, Xue, Maheshwari, Uma R., Venkat, Pooja, Mayoh, Chelsea, Gowda, Harsha, Kalimutho, Murugan, Hooper, John D. and Khanna, Kum Kum (2023). Combined thioredoxin reductase and glutaminase inhibition exerts synergistic anti-tumor activity in MYC-high high-grade serous ovarian carcinoma. Molecular Therapy, 31 (3) 212011, 729-743. doi: 10.1016/j.ymthe.2022.12.011
2023
Journal Article
Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancer
Lyons, Nicholas, Giri, Rabina, Begun, Jakob, Clark, David A, Proud, David, He, Yaowu, Hooper, John and Kryza, Thomas (2023). Reactive oxygen species as mediators of disease progression and therapeutic response in colorectal cancer. Antioxidants and Redox Signaling, 39 (1-3), 186-205. doi: 10.1089/ars.2022.0127
2022
Conference Publication
Development of antibody-drug conjugates targeting the CDCP1 receptor for the treatment of Triple negative and metastatic breast cancer
Gough, M., Kwah, K., Khan, T., He, Y., Pyke, C., Ratnayake, G., Snell, C., Hooper, J. and Kryza, T. (2022). Development of antibody-drug conjugates targeting the CDCP1 receptor for the treatment of Triple negative and metastatic breast cancer. 13th European Breast Cancer Conference (EBCC-13), Barcelona, Spain, 16-18 November 2022. Oxford, United Kingdom: Elsevier. doi: 10.1016/s0959-8049(22)01571-4
2022
Journal Article
CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy
Khan, Tashbib, Lyons, Nicholas J., Gough, Madeline, Kwah, Kayden K.X., Cuda, Tahleesa J., Snell, Cameron E., Tse, Brian W., Sokolowski, Kamil A., Pearce, Lesley A., Adams, Timothy E., Rose, Stephen E., Puttick, Simon, Pajic, Marina, Adams, Mark N., He, Yaowu, Hooper, John D. and Kryza, Thomas (2022). CUB Domain-Containing Protein 1 (CDCP1) is a rational target for the development of imaging tracers and antibody-drug conjugates for cancer detection and therapy. Theranostics, 12 (16), 6915-6930. doi: 10.7150/thno.78171
2021
Journal Article
Elevating CDCA3 levels enhances tyrosine kinase inhibitor sensitivity in TKI-resistant EGFR mutant non-small-cell lung cancer
Sahin, Katherine B., Shah, Esha T., Ferguson, Genevieve P., Molloy, Christopher, Kalita-de Croft, Priyakshi, Hayes, Sarah A., Hudson, Amanda, Colvin, Emily, Kamitakahara, Hannah, Harvie, Rozelle, Hasovits, Csilla, Khan, Tashbib, Duijf, Pascal H. G., Howell, Viive M., He, Yaowu, Bolderson, Emma, Hooper, John D., Lakhani, Sunil R., Richard, Derek J., O’Byrne, Kenneth J. and Adams, Mark N. (2021). Elevating CDCA3 levels enhances tyrosine kinase inhibitor sensitivity in TKI-resistant EGFR mutant non-small-cell lung cancer. Cancers, 13 (18) 4651, 4651. doi: 10.3390/cancers13184651
2021
Journal Article
Preclinical molecular PET-CT imaging targeting CDCP1 in colorectal cancer
Cuda, Tahleesa J., He, Yaowu, Kryza, Thomas, Khan, Tashbib, Tse, Brian W., Sokolowski, Kamil A., Liu, Cheng, Lyons, Nicholas, Gough, Madeline, Snell, Cameron E., Wyld, David K., Rose, Stephen, Riddell, Andrew D., Stevenson, Andrew R. L., Thomas, Paul A., Clark, David A., Puttick, Simon and Hooper, John D. (2021). Preclinical molecular PET-CT imaging targeting CDCP1 in colorectal cancer. Contrast Media and Molecular Imaging, 2021 3153278, 3153278. doi: 10.1155/2021/3153278
2021
Journal Article
Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer
He, Yaowu, Khan, Tashbib, Kryza, Thomas, Jones, Martina L., Goh, Justin B., Lyons, Nicholas J., Pearce, Lesley A., Lee, Michael D, Gough, Madeline, Rogers, Rebecca, Davies, Claire M,, Gilks, C. Blake, Hodgkinson, Thomas, Lourie, Rohan, Barry, Sinead C., Perrin, Lewis C., Williams, Charlotte C., Puttick, Simon, Adams, Timothy E., Munro, Trent P., Hooper, John D. and Chetty, Naven (2021). Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian Cancer. Molecular Pharmaceutics, 18 (9) acs.molpharmaceut.1c00401, 3464-3474. doi: 10.1021/acs.molpharmaceut.1c00401
2021
Journal Article
Extracellular vesicle transmission of chemoresistance to ovarian cancer cells is associated with hypoxia-induced expression of glycolytic pathway proteins, and prediction of epithelial ovarian cancer disease recurrence
Alharbi, Mona, Lai, Andrew, Sharma, Shayna, Kalita-De Croft, Priyakshi, Godbole, Nihar, Campos, America, Guanzon, Dominic, Salas-Burgos, Alexis, Carrion, Flavio, Zuñiga, Felipe A., Perrin, Lewis, He, Yaowu, Pejovic, Tanja, Winters, Carmen, Morgan, Terry, Hooper, John D., Rice, Gregory E. and Salomon, Carlos (2021). Extracellular vesicle transmission of chemoresistance to ovarian cancer cells is associated with hypoxia-induced expression of glycolytic pathway proteins, and prediction of epithelial ovarian cancer disease recurrence. Cancers, 13 (14) 3388, 1-26. doi: 10.3390/cancers13143388
2021
Journal Article
Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1
Kryza, Thomas, Khan, Tashbib, Lovell, Scott, Harrington, Brittney S., Yin, Julia, Porazinski, Sean, Pajic, Marina, Koistinen, Hannu, Rantala, Juha K., Dreyer, Tobias, Magdolen, Viktor, Reuning, Ute, He, Yaowu, Tate, Edward W. and Hooper, John D. (2021). Substrate-biased activity-based probes identify proteases that cleave receptor CDCP1. Nature Chemical Biology, 17 (7), 776-783. doi: 10.1038/s41589-021-00783-w
2021
Journal Article
The CDCP1 signalling hub: a target for cancer detection and therapeutic intervention
Khan, Tashbib, Kryza, Thomas, Lyons, Nicholas J., He, Yaowu and Hooper, John D. (2021). The CDCP1 signalling hub: a target for cancer detection and therapeutic intervention. Cancer Research, 81 (9) canres.2978.2020, QF1-QF11. doi: 10.1158/0008-5472.can-20-2978
2021
Journal Article
A nucleotide analog prevents colitis associated cancer via Β-catenin independently of inflammation and autophagy
Sheng, Yong Hua, Giri, Rabina, Davies, Julie, Schreiber, Veronika, Alabbas, Saleh, Movva, Ramya, He, Yaowu, Wu, Andy, Hooper, John, McWhinney, Brett, Oancea, Iulia, Kijanka, Gregor, Hasnain, Sumaira, Lucke, Andrew J., Fairlie, David P., McGuckin, Michael A., Florin, Timothy H. and Begun, Jakob (2021). A nucleotide analog prevents colitis associated cancer via Β-catenin independently of inflammation and autophagy. Cellular and Molecular Gastroenterology and Hepatology, 11 (1), 33-53. doi: 10.1016/j.jcmgh.2020.05.012
2020
Other Outputs
Substrate-biased activity-based probes identify the urokinase-plasminogen axis as a master regulator of metastatic signaling by orphan membrane receptor CDCP1
Kryza, Thomas, Khan, Tashbib, Lovell, Scott, Harrington, Brittney S., Yin, Julia, Porazinski, Sean, Pajic, Marina, Koistinen, Hannu, Rantala, Juha, Dreyer, Tobias, Magdolen, Viktor, Reuning, Ute, He, Yaowu, Tate, Edward and Hooper, John David (2020). Substrate-biased activity-based probes identify the urokinase-plasminogen axis as a master regulator of metastatic signaling by orphan membrane receptor CDCP1.
2020
Other Outputs
Binding proteins to CUB domain-containing protein (CDCP1)
Puttick, S., Kryza, T., Hooper, J. D., He, Y., Harrington, B., Quigley, J. and Deryugina, E. (2020). Binding proteins to CUB domain-containing protein (CDCP1). PCT/AU2020/051216.
Funding
Past funding
Supervision
Availability
- Dr Yaowu He is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Media
Enquiries
For media enquiries about Dr Yaowu He's areas of expertise, story ideas and help finding experts, contact our Media team: